ACTRN12610000287033招募中1 期
A phase I randomized, double-blind, placebo-controlled study inhealthy male volunteers to examine the safety, tolerability, and pharmacokinetics of HMPL-011 after multiple dosing for 14days.
Hutchison MediPharma0 个研究点目标入组 24 人开始时间: 2010年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Male
入选标准
- •Healthy male subjects having Body Mass Index (BMI) between 19 and 34 kg/m2
排除标准
- •Any significant acute or chronic medical condition. Volunteers at risk of tuberculosis(TB). Evidence of organ dysfunction or any clinically significant deviation from normal.
研究者
相似试验
已完成
不适用
A phase 1 randomized, double-blind, placebo-controlled, maximum tolerated dose escalation, safety, tolerability and pharmacokinetic adaptive study of RAD1901 administered to healthy postmenopausal womebrain metastasis10027656breast cancer10006232NL-OMON41865Radius Health, Inc.68
招募中
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System to Evaluate the Safety, Tolerability, and Pharmacokinetics of AP02 in Healthy Volunteers (AP02-002)Respiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12624000825550Avalyn Pharma, Inc.68
招募中
1 期
A Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of SION-451 in healthy participantsHuman Genetics and Inherited Disorders - Cystic fibrosisCystic FibrosisACTRN12624000849594Sionna Therapeutics, Inc96
尚未招募
1 期
A Phase 1 study to evaluate the safety and pharmacokinetics of single and multiple doses of SION-719 in healthy participantsHuman Genetics and Inherited Disorders - Cystic fibrosisRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12624000739516Sionna Therapeutics, Inc96
已完成
不适用
A phase I, double-blind, randomized, placebo-controlled, multicenter, Single- and multiple-ascending-dose study to determine initial safety, Tolerability, and pharmacokinetics of GDC-0134 in patients with amyotrophic Lateral sclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON46547Genentech, Inc.6